Clarithromycin-induced	clarithromycin-induced	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Clarithromycin	clarithromycin	O	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
relatively	relatively	O	O	O	O
new	new	O	O	O	O
macrolide	macrolide	O	O	OTHERS	I
antibiotic	antibiotic	O	O	O	O
that	that	O	O	O	O
offers	offers	O	O	O	O
twice-daily	twice-daily	O	O	O	O
dosing	dosing	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
differs	differs	O	O	O	O
from	from	O	O	O	O
erythromycin	erythromycin	O	O	OTHERS	I
only	only	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
methylation	methylation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
hydroxyl	hydroxyl	O	O	OTHERS	I
group	group	O	O	O	O
at	at	O	O	O	O
position	position	O	O	O	O
6	6	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
the	the	O	O	O	O
side-effect	side-effect	O	O	O	O
profile	profile	O	O	O	O
of	of	O	O	O	O
erythromycin	erythromycin	O	O	OTHERS	I
is	is	O	O	O	O
established	established	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
gastroenteritis	gastroenteritis	O	O	OTHERS	I
and	and	O	O	O	O
interactions	interactions	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
drugs	drugs	O	O	O	O
subject	subject	O	O	O	O
to	to	O	O	O	O
hepatic	hepatic	O	O	O	O
mixed-function	mixed-function	O	O	O	O
oxidase	oxidase	O	O	O	O
metabolism	metabolism	O	O	O	O
,	,	O	O	O	O
experience	experience	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
newer	newer	O	O	O	O
macrolides	macrolides	O	O	OTHERS	I
is	is	O	O	O	O
still	still	O	O	O	O
being	being	O	O	O	O
recorded	recorded	O	O	O	O
.	.	O	O	O	O

Cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
demonstrated	demonstrated	O	O	O	O
after	after	O	O	O	O
both	both	O	O	O	O
intravenous	intravenous	O	O	O	O
and	and	O	O	O	O
oral	oral	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
erythromycin	erythromycin	O	O	OTHERS	I
but	but	O	O	O	O
has	has	O	O	O	O
never	never	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
newer	newer	O	O	O	O
macrolides	macrolides	O	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
a	a	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
ventricular	ventricular	O	O	OTHERS	I
dysrhythmias	dysrhythmias	O	O	OTHERS	I
that	that	O	O	O	O
occurred	occurred	O	O	O	O
after	after	O	O	O	O
six	six	O	O	O	O
therapeutic	therapeutic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
clarithromycin	clarithromycin	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
dysrhythmias	dysrhythmias	O	O	OTHERS	I
resolved	resolved	O	O	O	O
after	after	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

